Astral's chemicals business demerger—covering adhesives and paints—has elicited contrasting brokerage responses. CLSA maintains a Hold with a target price of ₹1,475, citing improved focus but limited near-term impact. JPMorgan downgrades to Neutral, flagging demerger uncertainty, PVC price correction risks, and demand volatility, while remaining structurally positive on Astral over Supreme. Investec retains a Buy with a target price of ₹1,710, highlighting the creation of Astral Chemie as India's second-largest listed pure-play after Pidilite Industries, backed by strong adhesives and construction chemicals growth, healthy cash flow, and RoCE.
Astral Ltd: Q4 Profit Dips But Beats Estimates, Declares Dividend
Astral Limited's Q4 results show a 3.5% increase in consolidated revenue to ₹1,681.00 crore. Net profit slightly decreased by 1.3% to ₹179.00 crore, but beat analyst estimates. EBITDA rose to ₹302.00 crore with a marginal improvement in EBITDA margin. The company declared a final dividend of ₹2.25 per equity share.